Patient characteristics. Values are median (interquartile range) or as the n (%).
| Characteristics | Relapse, n = 36 | Remission, n = 24 | p |
|---|---|---|---|
| Age, yrs | 57.0 (43.5–21.0) | 55.5 (51.3–62.0) | 0.934 |
| Female | 12 (33.3) | 9 (37.5) | 0.740 |
| PR3-ANCA | 31 (86.1) | 20 (83.3) | 0.768 |
| BVAS v3 | 18.5 (13.3–21.0) | 18.5 (14.0–23.8) | 0.281 |
| GPA | 33 (91.7) | 22 (91.7) | 1.000 |
| MPA | 3 (8.3) | 2 (8.3) | 1.000 |
| Previous organ involvement | |||
| Arthralgia | 21 (58.3) | 13 (54.2) | 0.750 |
| Cutaneous | 15 (41.7) | 5 (20.8) | 0.094 |
| Eyes | 8 (22.2) | 5 (20.8) | 0.898 |
| ENT | 28 (77.8) | 20 (83.3) | 0.598 |
| Lung | 25 (69.4) | 17 (70.8) | 0.908 |
| Cardiovascular | 1 (2.8) | 3 (12.5) | 0.139 |
| Renal | 36 (100) | 24 (100) | — |
| Abdominal | 2 (5.6) | 3 (12.5) | 0.340 |
| Central nervous system | 1 (2.8) | 0 (0) | 0.410 |
| Peripheral nervous system | 7 (19.4) | 4 (16.7) | 0.785 |
| Therapy | |||
| Induction regimen with CYC/RTX | 23 (63.9) | 21 (87.5) | 0.043 |
| Current immunosuppressive therapy | 31 (86.1) | 18 (75.0) | 0.276 |
| Antibiotics maintenance therapy | 23 (63.9) | 16 (66.7) | 0.825 |
| ANCA rise | |||
| Time since previous disease activity, mos | 16.0 (8.5–25.8) | 13.0 (9.5–27.3) | 0.701 |
| Slope of the rise, % increase per day | 8.8 (4.6–15.9) | 4.9 (3.4–10.3) | 0.763 |
| Value at the rise | 37.5 (21.3–61.8) | 31.5 (21.0–48.5) | 0.970 |
| Concomitant IIF rise | 32 (88.9) | 21 (87.5) | 0.870 |
| Extended rise | 28 (77.8) | 8 (33.3) | 0.001 |
| Season | 0.028 | ||
| Winter | 9 (25.0) | 2 (8.3) | |
| Spring | 7 (19.4) | 9 (37.5) | |
| Summer | 9 (25.0) | 11 (45.8) | |
| Fall | 11 (30.6) | 2 (8.3) | |
| Followup | |||
| Persistently positive | 12 (33.3) | 9 (37.5) | 0.740 |
Significant data are in bold face. ANCA: antineutrophil cytoplasmic antibodies; PR3-ANCA: proteinase 3 ANCA; BVAS: Birmingham Vasculitis Activity Score; GPA: granulomatosis with polyangiitis; MPA: microscopic polyangiitis; CYC: cyclophosphamide; RTX: rituximab; IIF: indirect immunofluorescence.